<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR28">
 <label>28.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Gopal</surname>
    <given-names>AK</given-names>
   </name>
   <name>
    <surname>Tarantolo</surname>
    <given-names>SR</given-names>
   </name>
   <name>
    <surname>Bellam</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Green</surname>
    <given-names>DJ</given-names>
   </name>
   <name>
    <surname>Griffin</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Feldman</surname>
    <given-names>T</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients</article-title>
  <source>Investig New Drugs</source>
  <year>2014</year>
  <volume>32</volume>
  <fpage>1213</fpage>
  <lpage>1225</lpage>
  <pub-id pub-id-type="doi">10.1007/s10637-014-0125-2</pub-id>
  <pub-id pub-id-type="pmid">24927856</pub-id>
 </element-citation>
</ref>
